Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer - Gross, Mitchell E.; Agus, David B.; Dorff, Tanya B.; Pinski, Jacek K.; Quinn, David I.; Castellanos, Olga; Gilmore, Patrick; Shih, Jean C. (Prostate cancer and prostatic diseases, 2021)
Keywords: 692/308/575; 692/699/67/589/466; Adenocarcinoma - blood; Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Aged; Amine oxidase (flavin-containing); Antianxiety agents; Anxiety; Biochemistry; Biomarkers, Tumor - blood; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer surgery; Cancer therapies; Clinical trials; Depression, Mental; Disease-Free Survival; Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Edema; Follow-Up Studies; Humans; Hypertension; Inhibitors; Male; Medical colleges; Metastases; Metastasis; Middle Aged; Monoamine Oxidase Inhibitors - administration & dosage; Mood; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Oxidase; Oxidases; Patients; Phenelzine - administration & dosage; Post-radiation; Prostate cancer; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Questionnaires; Radiation therapy; Radiotherapy; Relapse; Syncope; Treatment Outcome; Urological surgery